Bergbosstraat 115 – Merelbeke 9820

The MWF is an international association of companies with an interest in mobile and wireless communications including the evolution to 5G and the Internet of Things.

Région Occitanie

Occitanie is an administrative region of France that was created on January 1, 2016 from the former French regions of Languedoc-Roussillon and Midi-Pyrénées. France’s Conseil d’État approved Occitanie as the new name of the region on September 28, 2016, coming into effect on September 30, 2016. The modern administrative region is named after the cultural and historical region of Occitania, which covers a larger area. The region as it is today covers a territory similar to that ruled by the Counts of Toulouse in the 12th and 13th centuries. The banner of arms of the Counts of Toulouse, known colloquially as the Occitan cross, is used by the modern region and is also a popular cultural symbol.

The new region covers an area of more than 72,724 km2 (28,079 square miles), and has a population of 5,626,858. It borders Nouvelle-AquitaineAuvergne-Rhône-AlpesProvence-Alpes-Côte d’AzurAndorra (CanilloEncampLa MassanaOrdino) and Spain (Aragon and Catalonia). [From Wikipedia]

The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with almost 300 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.

For more information on GSMA activities related to electromagnetic fields please visit

Telstra Corporation Limited
Telstra Corporate Centre, Melbourne

Telstra is Australia’s leading telecommunications and technology company, offering a full range of communications services and competing in all telecommunications markets.

In Australia we provide 17.7 million retail mobile services, 4.9 million retail fixed voice services and 3.6 million retail fixed broadband services.

We believe the more connected people are, the more opportunities they have. That’s why we help create a brilliant connected future for everyone, everyday.

That’s why we build technology and content solutions that are simple and easy to use, including Australia’s largest and fastest national mobile network.

That’s why we strive to serve and know our customers better than anyone else – offering a choice of not just digital connection, but digital content as well.

And that’s why we have an international presence spanning over 20 countries.

In the 21st Century, opportunity belongs to connected businesses, governments, communities and individuals.

As Australia’s leading telecommunications and information services company, Telstra is proud to be helping our customers improve the ways in which they live and work through connection.

Pulse Biosciences, Inc. – 3957 Point Eden Way
Hayward, California 94545

Tel: 510.906.4600

We are a development-stage medical device company using a novel and proprietary platform technology called Nano-Pulse Stimulation or NPS. NPS is a local and drug-free technology that utilizes ultra-short, nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. We believe that NPS can induce a variety of cellular responses including secretion, apoptosis and necrosis by modulating the NPS pulses, making it applicable to a wide variety of cell types and therapeutic applications.

One of the more promising applications of NPS is the treatment of solid tumors, where pre-clinical datadeveloped by Pulse Biosciences and others have shown that NPS provides effective local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the treated cells. We believe we will establish NPS as a new treatment modality across a variety of applications, including both veterinary and human oncology, dermatology, aesthetics and other minimally invasive applications where current ablation modalities do not provide the benefits of NPS.

We are developing a proprietary system for the delivery of NPS treatments, currently identified as the PulseTxTM system or “PulseTx.” The PulseTx system delivers NPS pulses through its proprietary tunable pulse generator and its suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes. For the treatment of cancer, we believe that we can trigger a signaling cascade within the tumor cells that ends in immunogenic apoptosis. Immunogenic apoptosis is a process in which cells are induced to die in a natural way, initiating their own programmed cell death, engaging the immune system to clear damaged, diseased, or aged cells and enrolling cytotoxic T cells to recognize and eliminate cells of the same tumor type. We believe we are the only medical device company with the intellectual property, technology, and know-how to be able to produce this natural cell death using NPS to initiate cell signaling that induces the targeted adaptive immune response.

Ecole Pratique des Hautes Études (EPHE)

L’École Pratique des Hautes Études est un grand établissement où l’on pratique la recherche en Sciences de la vie et de la terre, Sciences historiques et philologiques, et Sciences religieuses. Son enseignement est dispensé au niveau master, doctorat et post-doctorat ainsi que pour la préparation de son diplôme propre. Elle accueille depuis toujours des auditeurs libres.

L’EPHE couvre des territoires de la connaissance originaux. Participer aux conférences et autres enseignements qui y sont dispensés par plus de 260 enseignants-chercheurs, c’est pratiquer la recherche dans des champs aussi variés que les langues et les religions de l’Asie centrale pré-islamique, les grands monothéismes, l’archéologie chinoise, la paléographie hébraïque ou la dialectologie grecque et les humanités numériques pour les sciences humaines et sociales ; la biodiversité des récifs coralliens, les neurosciences et les cognisciences, l’environnement et la régulation cellulaires pour les sciences de la vie et de la terre… sans oublier les questions transdisciplinaires qui se posent à l’interface de ces grands domaines du savoir.

À sa création en 1868, l’EPHE avait pour mission d’introduire dans le monde universitaire un mode original de formation fondé sur la fréquentation de séminaires et le travail en laboratoire. Elle comprenait alors quatre sections : Mathématiques, Physique et chimie, Sciences naturelles et physiologie, et Sciences historiques et philologiques. Une Ve section de Sciences religieuses y fut adjointe en 1886. La VIe section, dévolue aux Sciences économiques et sociales, créée en 1947, s’autonomisa en 1975 pour devenir l’EHESS. À la même époque, les sections de mathématiques et de physique-chimie furent dissoutes.

Fidèle à sa mission initiale, l’EPHE continue de former à la recherche par la pratique de la recherche, mais en s’adaptant au nouveau paysage scientifique mondial : ses chercheurs et ses doctorants tissent un intense réseau international ; nombre de ses équipes sont contractualisées avec le CNRS ou d’autres organismes ; elle est membre de l’Université PSL où elle collabore avec d’autres prestigieux établissements ; elle est partie prenante du projet Campus Condorcet, la Cité des humanités et sciences sociales qui se bâtit à Aubervilliers.

Attentive aux enjeux sociétaux des questions scientifiques qu’elle étudie, l’EPHE a trois instituts qui offrent des formations et exercent une fonction d’observatoire : l’Institut européen en sciences des religions, l’Institut des récifs coralliens du Pacifique et l’Institut transdisciplinaire d’étude du vieillissement.

Institut National de la Santé et de la Recherche Médicale (INSERM)

The Institut national de la santé et de la recherche médicale (Inserm, the French National Institute of Health & Medical Research) is the only public sector research institution in France exclusively dedicated to human health. Under the dual aegis of the Ministries of Health and Research, Inserm has a budget of 998 million euros and employs 15,000 scientists, engineers and technicians all with one shared objective, namely to promote health—by advancing knowledge about living organisms and their diseases, developing innovative treatment modalities and conducting research on public health.

Inserm has more than 365 research units spread across France and internationally. These are supported by 13 Regional Commissions for local oversight. Scientific activities are organized around 9 “Inserm Thematic Institutes”, corresponding to the main fields of biomedical and health research.

Since its foundation in 1964, Inserm has played a part in many key, historic medical advances, including the first prenatal diagnostic tests, how the HLA system works, the first in vitro fertilisation, identification of the Human Immunodeficiency Virus, radiotherapy for cancer, the first skin grafting, deep brain stimulation and gene therapy.

Inserm is the leading academic patent applicant in European biomedical research, the 6th applicant in France across all sectors, the 2nd in the field of biotechnology and the first in pharmaceuticals (2016 European Patent Office figures).

In 2016, Inserm held a portfolio of 1,555 live patent families. Inserm Transfert, its private subsidiary responsible for managing the Institute’s intellectual property, has issued licenses for over a quarter of this portfolio to companies in France and around the world (including big commercial health care groups, intermediate-sized enterprises, SMEs or start-ups). On average, some ten spin- off companies are created each year.

In 2016, Inserm was the 9th most innovative public sector research institution in the world, according to Thomson-Reuters